Novel sulfamides and their use as endothelin receptor antagonists
申请人:——
公开号:US20040077670A1
公开(公告)日:2004-04-22
The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.
[EN] NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX SULFAMIDES ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR DE L'ENDOTHELINE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2002053557A1
公开(公告)日:2002-07-11
The invention relates to novel sulfamides of general formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.
Novel Sulfamides and their use as endothelin receptor antagonists
申请人:Actelion Pharmaceuticals Ltd.
公开号:EP1693372A1
公开(公告)日:2006-08-23
The invention relates to novel sulfamides of the general formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.